Alchemy Pharmatech, a Daresbury, UK-based company that has developed an intranasal delivery system, has received £400k in funding from SPARK Impact, manager of The North West Fund for Biomedical.
Led by founder and CTO Ian Harrison, Alchemy Pharmatech has developed a nasal delivery device for a range of pharmaceutical products including DNA vaccines, hormone replacement compounds and pain control products.
The company, which relocated to Daresbury Science and Innovation Park in April 2012, intends to use the capital to complete the development of its device for delivery of a specific compound, which will then be used in a human trial, to grow its management team, including the appointment of a full time CEO.
FinSMEs
11/06/2012